U
ANAC

UBS’s ANACOR PHARMACEUTICALS INC COM ANAC Stock Holding History

UBS’s Portfolio ANAC Stock Details ANAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-100
Closed -$2K – 11500
2014
Q1 		$2K Buy
+100
New +$1.94K ﹤0.01% 10172
2013
Q3 		– Sell
-700
Closed -$4K – 11373
2013
Q2 		$4K Buy
+700
New +$4.24K ﹤0.01% 9559

Other funds holding ANAC

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS's ANAC Position: Q3 2014 in Review

UBS reduced its ANACOR PHARMACEUTICALS INC COM (ANAC) stake by 0.25% in Q3 2014, selling an estimated $8.17K and leaving 162,808 shares worth $3.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2253.

UBS first reported a position in ANAC in Q2 2013 and has held it in 6 quarters since. 116 funds tracked by Wall St. Rank hold ANAC as of Q3 2014.

  • UBS held 162,808 shares of ANACOR PHARMACEUTICALS INC COM worth $3.98M as of Q3 2014.
  • UBS sold 402 ANACOR PHARMACEUTICALS INC COM shares in Q3 2014, an estimated $8.17K.
  • ANACOR PHARMACEUTICALS INC COM made up ﹤0.01% of UBS's portfolio in Q3 2014, its #2253 holding.
  • UBS first reported a position in ANACOR PHARMACEUTICALS INC COM in Q2 2013 and has held it in 6 quarters since.
  • 116 funds tracked by Wall St. Rank held ANACOR PHARMACEUTICALS INC COM as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.